Novo Nordisk NVO and Viking Therapeutics VKTX both operate in the obesity-treatment market. Novo Nordisk is recognized as a leader in the GLP-1 treatment space, marketing its semaglutide drugs under the brands Ozempic (injection and oral pill) and Rybelsus (pill) for type II diabetes (T2D) and Wegovy (injection and pill) for chronic weight management. In contrast, Viking is a clinical-stage biotech developing its investigational dual GIP and GLP-1 receptor agonist, VK2735, as both oral and injectable formulations across separate late-stage studies.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.